Detriflow 2Mg Tablets 28S (Pack Size 2 X 14S)
Brand : almed laboratories
Requires Prescription (YES/NO)
How it works
Tolterodine acts as a competitive antagonist of acetylcholine at postganglionic muscarinic receptors. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. After oral administration, tolterodine is metabolized in the liver, resulting in the formation of 5-hydroxymethyl tolterodine (5-HMT), the major pharmacologically active metabolite. 5-HMT, which exhibits an antimuscarinic activity similar to that of tolterodine, contributes significantly to the therapeutic effect. Both tolterodine and 5-HMT exhibit a high specificity for muscarinic receptors, since both show negligible activity or affinity for other neurotransmitter receptors and other potential cellular targets, such as calcium channels.
USAGE AND SAFETY
Dry mouth , Headache , Constipation , Stomach pain .
Potent CYP2D6 Inhibitors e.g. Fluoxetine , Potent CYP3A4 Inhibitors e.g. Ketoconazole , itraconazole, clarithromycin, or ritonavir .
It is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency .
When not to Use
It is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma.It is also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like Tolterodine Tartrate, are metabolized to 5-hydroxymethyl tolterodine .
Anaphylaxis and angioedema requiring hospitalization and emergency medical treatment have occurred with the first or subsequent doses of Tolterodine Tartrate. In the event of difficulty in breathing, upper airway obstruction, or fall in blood pressure, it should be discontinued and appropriate therapy promptly provided.
Administer Tolterodine Tartrate with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention .
Administer Tolterodine Tartrate with caution in patients with gastrointestinal obstructive disorders because of the risk of gastric retention. Tolterodine Tartrate , like other antimuscarinic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions associated with decreased gastrointestinal motility (e.g., intestinal atony) .
Tolterodine Tartrate is associated with anticholinergic central nervous system (CNS) effects including dizziness and somnolence . Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose. Advise patients not to drive or operate heavy machinery until the drug's effects have been determined. If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.
Always consult your physician before using any medicine.
Store this medicine at room temperature, away from direct light and heat.